Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like they did in the case of Tandem Diabetes Care, Inc. (NASDAQ:TNDM), that sends out a positive message to the company's shareholders.
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we do think it is perfectly logical to keep tabs on what insiders are doing.
View our latest analysis for Tandem Diabetes Care
Tandem Diabetes Care Insider Transactions Over The Last Year
The Executive VP & COO, David Berger, made the biggest insider sale in the last 12 months. That single transaction was for US$201k worth of shares at a price of US$65.00 each. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The silver lining is that this sell-down took place above the latest price (US$57.26). So it may not tell us anything about how insiders feel about the current share price.
Happily, we note that in the last year insiders paid US$511k for 7.00k shares. On the other hand they divested 3.50k shares, for US$244k. In total, Tandem Diabetes Care insiders bought more than they sold over the last year. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
NasdaqGM:TNDM Insider Trading Volume September 18th 2022
There are always plenty of stocks that insiders are buying. So if that suits your style you could check each stock one by one or you could take a look at this free list of companies. (Hint: insiders have been buying them).
Insider Ownership Of Tandem Diabetes Care
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. We usually like to see fairly high levels of insider ownership. It appears that Tandem Diabetes Care insiders own 0.5% of the company, worth about US$20m. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.
What Might The Insider Transactions At Tandem Diabetes Care Tell Us?
There haven't been any insider transactions in the last three months -- that doesn't mean much. But insiders have shown more of an appetite for the stock, over the last year. Insiders do have a stake in Tandem Diabetes Care and their transactions don't cause us concern. Of course, the future is what matters most. So if you are interested in Tandem Diabetes Care, you should check out this free report on analyst forecasts for the company.
Of course Tandem Diabetes Care may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
通常情況下,當一個內部人士購買股票時,可能不會是一個重大事件。但當多個內部人士都在買入,就像他們在Tandem糖尿病護理公司(納斯達克:TNDM),這向公司股東發出了一個積極的信息。
雖然我們永遠不會建議投資者應該完全根據公司董事的所作所為做出決定,但我們確實認為,密切關注內部人士的所作所為是完全合乎邏輯的。
查看我們對串聯糖尿病護理的最新分析
去年Tandem糖尿病護理內幕交易
執行副總裁兼首席運營官大衞·伯傑在過去12個月中進行了最大規模的內幕交易。這一筆交易是以每股65.00美元的價格收購了價值20.1萬美元的股票。我們通常不喜歡看到內幕銷售,但售價越低,我們就越擔心。一線希望是,這次拋售發生在最新價格(57.26美元)之上。因此,它可能不會告訴我們任何關於內部人士對當前股價的感受。
令人高興的是,我們注意到,在去年,內部人士支付了51.1萬美元購買了7.00萬股。另一方面,他們以24.4萬美元的價格剝離了3.5萬股。總體而言,Tandem糖尿病護理內部人士在過去一年裏買的比賣的多。你可以在下面看到過去12個月(由公司和個人)進行的內幕交易的直觀描述。通過點擊下面的圖表,你可以看到每一筆內幕交易的準確細節!
NasdaqGM:TNDM內幕交易量2022年9月18日
內部人士總是在買入大量股票。因此,如果這適合你的風格,你可以逐一檢查每一種庫存,或者你可以看看這個免費公司名單。(提示:內部人士一直在買入這些股票)。
串聯糖尿病護理的內部人所有權
另一種測試公司領導人與其他股東之間一致性的方法是看他們擁有多少股份。我們通常希望看到相當高水平的內部人士持股。似乎Tandem糖尿病護理內部人士擁有該公司0.5%的股份,價值約2000萬美元。我們當然在其他地方看到了更高水平的內部人持股,但這些持股足以表明內部人和其他股東之間的關係。
Tandem糖尿病護理公司的內幕交易可能告訴我們什麼?
過去三個月沒有發生任何內幕交易--這並不意味着什麼。但在過去一年裏,內部人士對該股表現出了更大的興趣。內部人士確實擁有Tandem糖尿病護理公司的股份,他們的交易不會引起我們的擔憂。當然了,未來才是最重要的。因此,如果你對串聯糖尿病護理感興趣,你應該看看這個免費分析師對該公司的預測報告。
當然了Tandem糖尿病護理可能不是購買的最佳股票。所以你可能想看看這個免費彙集了高質量的公司。
就本文而言,內部人是指向相關監管機構報告其交易的個人。我們目前負責公開市場交易和私人處置,但不包括衍生品交易。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。